drugset / Trial / NCT00995449
Study of KB003 In Biologics-Inadequate Rheumatoid Arthritis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and efficacy of various repeat-dose regimens of KB003 in subjects with active Rheumatoid Arthritis (RA) who have had an inadequate prior treatment outcome from biologic therapy.
Timeline
- Start
- 2010-01
- Primary completion
- 2011-03
- Completion
- 2012-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenzilumab | Monoclonal antibody | 70 mg | Intravenous |
| Subject | Lenzilumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Lenzilumab | Monoclonal antibody | 600 mg | Intravenous |